Rhoda Munene
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rhoda Munene has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alain M’bOngo Zindamoyen
PCEA Kikuyu Eye Unit, Kikuyu, Kenya
3 shared publications - Ernest Ollando
Sabatia Eye Hospital, Wodanga, Kenya
3 shared publications - Helen Anne Weiss
International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK
3 shared publications - Hillary Rono
London School of Hygiene and Tropical Medicine
3 shared publications - Joseph Wachira
Kenyatta National Hospital, Nairobi, Kenya
3 shared publications - Joy Kabiru
PCEA Kikuyu Eye Unit, Kikuyu, Kenya
3 shared publications
Latest Publications
- Open Access
- 14 July 2017
- Published by Springer Nature in BMC Health Services Research
- Vol. 17 (1) , 1-11
Delay along the care-seeking journey of patients with ocular surface squamous neoplasia in Kenya
In Africa, accessing eye health services is a major challenge. Ocular surface squamous neoplasia (OSSN) is a substantial ocular health problem in Africa related to solar UV light exposure and HIV infection among other risk factors. The disease causes visual loss and even death in advanced cases. This study was conducted to assess referral pathway and treatment delay for patients with OSSN in Kenya. Adults with conjunctival lesions presenting to four eye centres were asked about their occupations, when they noticed the growth, health facilities visited in seeking care, cost of consultation, surgery, medicines and histopathology and dates at each step. The time-to-presentation was divided into quartiles and correlates analysed using ordinal logistic regression. We evaluated 158 first-time presenters with OSSN. Most were women (102 [65%]), living with HIV (78/110 tested [71%]), with low to medium income (127 [80%]). Most of the HIV patients (49/78 [63%]) were in antiretroviral care programs. About half (88/158, [56%]) presented directly to the study centres while the rest were referred. Indirect presenters sought care earlier than direct presenters (median 2.0 months vs 5.5 months) and travelled a shorter distance to the first health facility (median 20 km vs 30 km) but had surgery later (median 12.5 months vs 5.5 months). Visits beyond the first health facility for indirect presenters markedly increased delay (median 7.3, 29.0, 37.9, and 32.0 months for 1–4 facilities, respectively). Delay was associated with number of health facilities visited (adjusted ordered OR = 9.12; 95%CI 2.83–29.4, p < 0.001) and being female (adjusted ordered OR = 2.42; 95%CI 1.32–4.44, p = 0.004). At the time of presentation at the study centres for surgery the median tumour diameter in both directly and indirectly presenting patients was 6 mm (p = 0.52) and the histological spectrum of OSSN was similar between the groups (p = 0.87). Referral delays definitive treatment for OSSN. Women were more likely to experience delay. Despite regular contact with the health system for those with known HIV infection, delays occurred. Early detection and referral of OSSN in the HIV service might reduce delays, but reassuringly delay did not give rise to a larger proportion with more advanced grade of OSSN.
- 14 July 2017
- Published by Springer Nature in BMC Health Services Research
- Vol. 17 (1) , 1-11
Open AccessDelay along the care-seeking journey of patients with ocular surface squamous neoplasia in Kenya
In Africa, accessing eye health services is a major challenge. Ocular surface squamous neoplasia (OSSN) is a substantial ocular health problem in Africa related to solar UV light exposure and HIV infection among other risk factors. The disease causes visual loss and even death in advanced cases. This study was conducted to assess referral pathway and treatment delay for patients with OSSN in Kenya. Adults with conjunctival lesions presenting to four eye centres were asked about their occupations, when they noticed the growth, health facilities visited in seeking care, cost of consultation, surgery, medicines and histopathology and dates at each step. The time-to-presentation was divided into quartiles and correlates analysed using ordinal logistic regression. We evaluated 158 first-time presenters with OSSN. Most were women (102 [65%]), living with HIV (78/110 tested [71%]), with low to medium income (127 [80%]). Most of the HIV patients (49/78 [63%]) were in antiretroviral care programs. About half (88/158, [56%]) presented directly to the study centres while the rest were referred. Indirect presenters sought care earlier than direct presenters (median 2.0 months vs 5.5 months) and travelled a shorter distance to the first health facility (median 20 km vs 30 km) but had surgery later (median 12.5 months vs 5.5 months). Visits beyond the first health facility for indirect presenters markedly increased delay (median 7.3, 29.0, 37.9, and 32.0 months for 1–4 facilities, respectively). Delay was associated with number of health facilities visited (adjusted ordered OR = 9.12; 95%CI 2.83–29.4, p < 0.001) and being female (adjusted ordered OR = 2.42; 95%CI 1.32–4.44, p = 0.004). At the time of presentation at the study centres for surgery the median tumour diameter in both directly and indirectly presenting patients was 6 mm (p = 0.52) and the histological spectrum of OSSN was similar between the groups (p = 0.87). Referral delays definitive treatment for OSSN. Women were more likely to experience delay. Despite regular contact with the health system for those with known HIV infection, delays occurred. Early detection and referral of OSSN in the HIV service might reduce delays, but reassuringly delay did not give rise to a larger proportion with more advanced grade of OSSN.
- Open Access
- 1 November 2015
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 133 (11) , 1314-1321
Toluidine Blue 0.05% Vital Staining for the Diagnosis of Ocular Surface Squamous Neoplasia in Kenya
Ocular surface squamous neoplasia (OSSN) is an aggressive eye cancer, particularly affecting young adults in Africa, causing visual disability and high morbidity and mortality. The diagnosis is problematic. In most African countries, pathology services are limited; most clinicians depend on their clinical judgment.1,2 However, the appearance of OSSN overlaps with several benign conditions, making a clinical impression unreliable. Surgical excision is the mainstay of OSSN treatment. For example, a simple diagnostic test would help clinicians plan management by better delineating the boundaries of the lesion during excision. The test may also help in distinguishing early recurrent tumor from nonmalignant abnormal tissue, such as fibrosis, possibly avoiding the need for additional surgery.
- 1 November 2015
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 133 (11) , 1314-1321
Open AccessToluidine Blue 0.05% Vital Staining for the Diagnosis of Ocular Surface Squamous Neoplasia in Kenya
Ocular surface squamous neoplasia (OSSN) is an aggressive eye cancer, particularly affecting young adults in Africa, causing visual disability and high morbidity and mortality. The diagnosis is problematic. In most African countries, pathology services are limited; most clinicians depend on their clinical judgment.1,2 However, the appearance of OSSN overlaps with several benign conditions, making a clinical impression unreliable. Surgical excision is the mainstay of OSSN treatment. For example, a simple diagnostic test would help clinicians plan management by better delineating the boundaries of the lesion during excision. The test may also help in distinguishing early recurrent tumor from nonmalignant abnormal tissue, such as fibrosis, possibly avoiding the need for additional surgery.
- Open Access
- 1 November 2015
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 133 (11) , 1305-1313
Clinical Presentation of Ocular Surface Squamous Neoplasia in Kenya
Ocular surface squamous neoplasia (OSSN) is a spectrum of disease ranging from noninvasive intraepithelial dysplasia of the conjunctiva and cornea to invasive squamous cell carcinoma.1 Worldwide, the incidence of OSSN is highest in the southern hemisphere (16°S), with the peak occurring in Africa.2
- 1 November 2015
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 133 (11) , 1305-1313
Open AccessClinical Presentation of Ocular Surface Squamous Neoplasia in Kenya
Ocular surface squamous neoplasia (OSSN) is a spectrum of disease ranging from noninvasive intraepithelial dysplasia of the conjunctiva and cornea to invasive squamous cell carcinoma.1 Worldwide, the incidence of OSSN is highest in the southern hemisphere (16°S), with the peak occurring in Africa.2